![[Leu15]-Gastrin I (human)](https://file.medchemexpress.com/product_pic/hy-p2671.gif "Click to View [Leu15]-Gastrin I (human) Product Detail")
![[Tyr4]-Bombesin](https://file.medchemexpress.com/product_pic/hy-w343750.gif "Click to View [Tyr4]-Bombesin Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
60 Results for "
gastrin receptor
" in MedChemExpress (MCE) Product Catalog:
Products (60)
60 Results for "gastrin receptor" in MCE Product Catalog:
18
18 Publications Verification
Cat. No.: HY-P1097
CAS No.: 10047-33-3
Target:
Research Areas:
2
2 Cited Publications
Target:
Research Areas:
PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells.
2
2 Cited Publications
Target:
Research Areas:
L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .
2
2 Cited Publications
Target:
Research Areas:
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .
2
2 Cited Publications
Cat. No.: HY-106840A
Purity: 99.75%
Target:
Research Areas:
L-365260 hemihydrate is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors .
1
1 Cited Publications
Cat. No.: HY-P2671
CAS No.: 39024-57-2
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P0195
CAS No.: 31362-50-2
Category:
Target:
1
1 Cited Publications
Synonyms: Netazepide; YF 476; YM-220
Target:
Research Areas:
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively .
1
Target:
Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt
Research Areas:
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
1
1 Cited Publications
Cat. No.: HY-P0107A
CAS No.: 1217463-61-0
Target:
Research Areas:
1
1 Cited Publications
Synonyms: Cholecystokinin tetrapeptide; CCK-4
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P0107
CAS No.: 138147-78-1
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-103277A
Purity: 96.20%
Target:
Research Areas:
Target:
Research Areas:
PD 168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with the Ki of 15–45 nM . PD 168368 is neuromedin B receptor (NMBR; IC50=96 nM) / gastrin-releasing peptide receptor (GRPR IC50=3500 nM) antagonist . PD 168368 also is a mixed FPR1/FPR2/FPR3 agonist with EC50s of 0.57, 0.24, and 2.7 nM, respectively .
Cat. No.: HY-P1423A
Target:
Research Areas:
Cat. No.: HY-101005
CAS No.: 16503-22-3
Synonyms: Nα-Methylhistamine dihydrochloride
Target:
Research Areas:
N-Methylhistamine dihydrochloride (Nα-Methylhistamine dihydrochloride) is a non-selective Histamine receptor agonist. N-Methylhistamine dihydrochloride activates histamine H1, H2 and H3 receptors; it stimulates central H1 receptors by activating sympathetic α and β adrenergic receptors to inhibit intestinal transit, exerts dose-dependent inhibition on intestinal transit, reduces histamine turnover in mouse brains, and increases gastric acid secretion without altering plasma gastrin concentrations. N-Methylhistamine dihydrochloride produces a pH-dependent, voltage-independent potentiating effect on acid-sensing ion channel 1a, and shows no significant activity toward homologous ASIC2a channels. N-Methylhistamine dihydrochloride can be used in studies related to Helicobacter pylori infection .
Category:
Alkaloids Animals Metabolic Disease Plants Solanaceae Disease Research Fields Datura metel Linn. Indole Alkaloids
Target:
Cat. No.: HY-P0039
CAS No.: 136207-23-3
Target:
Research Areas:
Cat. No.: HY-P10896
CAS No.: 1446005-10-2
Target:
Research Areas:
Cat. No.: HY-W343750
CAS No.: 67338-70-9
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
